PSME2

Across TCGA pan-cancer cohorts, PSME2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSME2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSME2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSME2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where PSME2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.903	0.609	.007	12	view →
HNSC	DFS	Median	IV	0.768	0.542	.026	7	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	7	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.077	.024	3	view →
GBM	OS	Quartile	All	0.475	0.669	.040	2	view →
LSCC	DFS	Quartile	All	1.000	0.354	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSME2–LUAD (DFS)

Open the LUAD breakdown →